Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

67.66 +0.74 (+1.11%)

Official Closing Price Updated: 6:30 PM EDT, Sep 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

Today 15:30 EDT

The company is coming back into the spotlight thanks to recent developments.

Via The Motley Fool

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

Today 12:50 EDT

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Via The Motley Fool

Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

August 31, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons to Sell BMY and 1 Stock to Buy Instead

August 31, 2026

Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d...

Via StockStory

Topics Stocks

Bristol-Myers Squibb (NYSE:BMY) Surges on Q2 Earnings Beat, Raises Full-Year Guidance ↗

July 30, 2026

Via Chartmill

Topics Earnings

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Via The Motley Fool

Topics Intellectual Property

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

August 28, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

3 Dividend Stocks to Hold for the Next 10 Years ↗

August 25, 2026

These healthcare leaders are unlikely to suspend their dividend programs.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗

August 21, 2026

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Via The Motley Fool

Topics ETFs

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

August 20, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)

August 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

August 18, 2026

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Via The Motley Fool

1 Momentum Stock on Our Buy List and 2 We Turn Down

August 17, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Via StockStory

Are Mega-Mergers Back? ↗

August 15, 2026

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 14, 2026

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

Via The Motley Fool

Topics Intellectual Property

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

Via The Motley Fool

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗

August 11, 2026

This problem has a solution, and Pfizer is implementing it.

Via The Motley Fool

Topics Intellectual Property

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

August 10, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 06, 2026

Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Managemen...

Via StockStory

Topics Earnings

Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Via The Motley Fool

Topics Earnings

Which S&P500 stocks are moving before the opening bell on Monday? ↗

August 03, 2026

Via Chartmill

Bristol Myers Squibb Isn't Nearly as Cheap as It Looks -- Here's the 1 Thing That Could Change That ↗

August 01, 2026

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Q2 Earnings Call Highlights ↗

August 01, 2026

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio....

Via MarketBeat

Topics Earnings

BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook

July 31, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Via StockStory

Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Via The Motley Fool

Topics Earnings

Why Bristol Myers Squibb Stock Topped the Market on Thursday ↗

July 30, 2026

It notched convincing beats on analyst estimates with its second-quarter performance.

Via The Motley Fool

Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About ↗

July 30, 2026

Things are going well for the pharmaceutical giant.

Via The Motley Fool

Topics Lawsuit

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

July 30, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Via StockStory

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

July 28, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for. Bristol-Myers ...

Via StockStory

This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock? ↗

July 28, 2026

Bristol Myers keeps making moves to establish a strong foundation for the future.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.